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Abstract
This article discusses possible applications of cells derived from human amniotic fluid in regenerative medicine,
specifically in stroke therapy. Recent studies have evaluated amniotic fluid as a viable source for mesenchymal stem
cells in the expansion of cell-based transplantation. Laboratory data have demonstrated the ability of amniotic fluid
stem cells (AFSC) to act as biobridges or subdural patch-like networks when treating traumatic brain injury (TBI).
Also AFSCs have been shown to differentiate along the neuronal lineage following transplantation in animal
models of brain disorders. In addition to the cells’ many clinical applications, AFSCs can be harvested without
raising any ethical concern. This paper evaluates the characteristics of AFSCs, along with the functional benefits of
using the cells in animal stroke models, reinforcing the potential advantages of deriving stem cells from amniotic
fluid, for stroke treatment.
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Background
Recent studies have identified human amnion and amni-
otic fluid as potential stem cell sources with clinical
significance in the field of regenerative medicine. Several
investigations have evaluated the differentiation potential
of cells from both the amnion and amniotic fluid, dem-
onstrating that these cells exhibit high plasticity [1]. The
majority of studies target amnion stem cells, revealing
their tendency to promote re-epithelization, modulate
differentiation and angiogenesis, and reduce inflamma-
tion, apoptosis, and fibrosis following transplantation
[1–4]. Accumulating evidence have now similarly shown
stemness of the lesser studied amniotic fluid-derived
stem cells (AFSCs). Unlike AMSCs, AFSCs have a differ-
ent mode of collection, allowing for different treatment
options for diseases with different time-frames of stem
cell administration. Here, we discuss AFSCs’ significance
for stroke therapy in the clinical setting. Moreover, we
compare the benefits and drawbacks of AFSCs and
amnion membrane stem cells.
Stemness of cells derived from the amniotic fluid
The presence of particular pluripotency markers and
genes in cells obtained from amniotic fluid classifies
these cells as stem cells. In a recent study by Antonucci
et al. [5], molecular analysis revealed that human second
trimester AFSCs express Fragilis, Stella, Vasa, c-Kit, and
Rnf17, genes coordinating the early stages of germ cell
development, along with OCT4 and SOX2, indicators of
pluripotency. Aggregated AFSCs form embryoid bodies
(EBs) which regain pluripotency potential and they mod-
estly retain features of early stage embryogenesis. In
addition, alternate spliced exons explicit of pluripotent
stem cells have been observed in cells from AFSC-
derived EBs, such as the b isoform of Sall4 and the exon
10 of DNMT3B. These exons display markers of the
three embryonic germ layers, such as GATA4, GATA6,
AFP and Nestin, and X chromosome inactivation
appears to be lacking [5]. The reactivation of the dor-
mant X chromosome may be associated with genomic
reprogramming events, further supporting the significant
role of AFSCs in embryogenesis [5]. CD117-negative
populations of human amniotic fluid mesenchymal stro-
mal cells (AFMSCs) are not only readily abundant for
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therapeutic use, but can also easily differentiate into
induced pluripotent stem cells (iPSCs) with the use of
nonintegrating Sendai viral vectors encoding for OCT4,
SOX2, KLF4 and cMYC [6]. Moreover, Jiange et al. [6]
have revealed the potential of iPSCs to imitate human
embryonic stem cells, noting their ability to form rela-
tively homogenous populations of neural progenitors,
and to show engraftment potential in vivo. In vitro, these
neural progenitor cells display the ability to differentiate
into astrocytes and mature neurons [6].
In a similar study conducted by Antonucci et al.
AFMSCs were shown to have gene expression profiles
similar to those in undifferentiated cells [7]. RT-PCR
analysis revealed that AFMSCs express genes for SCF,
GATA-4, Rex-1, CK18, vimentin, HLA ABC, and FG-5
in culture, along with BMP-4, nestin, HNF-4α, and AFP
[7]. This is a notable discovery, because the aforemen-
tioned genes regulate a diverse array of cell types,
indicating the ability of AFMSCs to differentiate into a
multitude of cell types including adipocytes, chondro-
cytes, neuronal cells and osteocytes [7]. These observa-
tions suggest that AFMSCs can exhibit many pluripotent
stem cell specific genes and proliferate well through
ex vivo expansion [7].
Although laboratory findings provide evidence of
therapeutic potential of AFMSCs based on the cells’
ability to differentiate into all three germ layers in vitro,
AFMSCs are known for having low immunogenicity and
therefore are still being tested for their immunologic
characteristics. Studies have shown AFMSCs to express
immunosuppressive factors such as CD59 (protectin)
and HLA-G, resulting in AFMSCs being resistant to
rejection [8]. CD59 hinders the complement membrane
attack complex by binding C5b678 and obstructing C9
from binding and polymerizing, therefore averting the
complement from damaging cells [8]. HLA-G, is present
within the placenta which is distinct from HLA-A and
HLA-B genes, and stands as an important factor in
immune tolerance in pregnancy, thereby allowing
AFMSC graft resistance [8]. Additionally, other studies
have shown the ability of AFMSCs to modulate the im-
mune system, leading to restriction of T lymphocyte
proliferation [8]. Moreover, increased CD105+ levels
were found in the late-passage of the cell culture in
contrast to the early-passage ASFC culture [9]. This
provides evidence of AFSCs role as a mesenchymal
precursor, in that the prevalence of CD105 and the long-
term culture conditions permit mesenchymal cell growth
[9]. A recent in vitro investigation determined the gesta-
tional age (i.e., those derived from first-, second-to third-
trimester) that influence AFSCs’ function in regulating
the proliferation of lymphocytes [10]. Interestingly, first-
trimester AFSCs considerably hindered natural killer cell
and T cell proliferation, while second- and third-
trimester AFSCs were far less effective and only the
inflammatory-primed second-trimester AFSCs could
restrict B-cell proliferation [10].
As noted above, AFSCs exhibit features of both
embryonic and adult stem cells, but such phenotypic
characteristics may vary dependent on the donor [11].
Notwithstanding, these stemness characteristics of
AFSCs do not inhibit the differentiation capacity of
AFMSC preparation, although the ectopic expression of
Oct-4 in hAFMSCs could be a secondary factor in
achieving pluripotency [12], while the selective expres-
sion of SOX9 and introduction of Wnt signaling can be
used to explicitly differentiate cells into neurons and
promote neurogenesis [13, 14]. However, before these
procedures can be initiated, an appropriate cyropreser-
vative protocol must be identified, such as a slow freez-
ing solution [15]. In their recent study, Zong et al. not
only found the ability of AFSCs to differentiate into
functional neurons using inner stem cells as a feeder
layer, but also identified the Wnt signaling pathway as
an integral aspect of initiating neurogenesis [16]. These
diverse properties and applications of AFSCs continue to
suggest their essential role in stroke therapy.
AFSCs and stroke
Stroke accounts for an outstanding number of deaths
each year, one of every nineteen deaths [17], but treat-
ment options are often limited. Intravenous recombinant
tissue plasminogen activator (tPA) is the only nationally
approved treatment for acute ischemic stroke, and while
this thrombolytic therapy affords positive aspects, for
instance, the reduction of deaths and decrease of
dependence for daily activities, it also has several detri-
mental side effects [18]. Thrombolytic therapy can only
be administered in a 4.5-h window post stroke and also
results in increased mortality at 7–10 days following
treatment, along with elevated risks of intracranial
hemorrhage resulting in death at 3 to 6 months follow-
ing the initial ischemic event [18].
An emerging treatment option for stroke is intraven-
ous delivery of bone marrow and perinatal-derived cells,
which have been shown in the laboratory as successfully
arresting the secondary cell death, even when initiated
within the first week post-stroke onset, thus markedly
extending the therapeutic window [19]. Nonetheless,
optimizing the timing of cell transplantation must be
taken into account since the stroke brain, unlike periph-
eral organs that succumb to ischemic insults, presents
with immediate cell death processes from the onset that
rapidly progress to debilitating brain dysfunctions [20].
Transplantation of AFSCs has been explored in brain
disorders, demonstrating their ability to differentiate along
a neural lineage [7, 21–25], along with other regenerative
features that promote restorative mechanisms, such as
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angiogenesis, immunomodulation, neurogenesis and
provide functional improvement [20]. Although AFSC
transplantation stands as a promising clinical treatment
for stroke, few studies have explored these cells as a
source for transplantation in stroke. In one experimental
stroke study, the transplantation of AFSCs led to a signifi-
cant reduction of brain damage that accompanied behav-
ioral recovery [26]. AFSCs may be an alternative graft
source to embryonic neuronal stem cells, which are often
difficult to study due to ethical concerns [26]. Because of
the inherent anti-inflammatory effects of AFSCs, they
appear as appropriate donor cells for stroke and other
neurological disorders characterized by a substantial
neuroinflammation [27]. Preclinical data also reveal that
AFSC transplantation improves cardiac function, suggest-
ing that these cells can be used on patients with stroke
presenting with cardiovascular etiology [28]. In translating
AFSCs for clinical application, consideration on the phase
of stroke (acute or chronic) may dictate the cell delivery
route of AFSCs. In addition, the timing of transplantation
of AFSCs, regardless of the stroke phase, may depend on
the ready availability of cryopreserved cells [27]. Our la-
boratory has investigated AFSC therapy in chronic stroke
rats, i.e., 1 month after induction of experimental ischemic
insult, and showed that AFSC transplantation reduces
deficits in memory and learning, decreases infarct volume
and neuron damage, and increases cell proliferation [29].
Advantages & disadvantages of amniotic fluid versus
amnion membrane stem cells
AFSCs and amnion membrane-derived stem cells
(AMSCs) have various advantages and disadvantages.
One notable advantage of AFSCs over AMSCs is that
amniotic fluid can be collected via amniocentesis, allow-
ing the cells to be isolated, cultured and amplified before
childbirth, which may permit the child’s own stem cells
to be immediately used for therapeutic purposes in any
emergency treatment following delivery. Such ready
availability of AFSCs enables for a more efficient thera-
peutic window. In contrast, it takes weeks to amplify
AMSCs from the amnion membrane, limiting the feasi-
bility of autologous AMSCs when contemplating of
treatment intervention at childbirth. In this regard, the
child can benefit from his/her own AFSCs, as autologous
transplantation due to the cells’ earlier harvesting period.
On the other hand, AMSCs pose as feasible graft source
for allogeneic transplantation because of the delayed
harvest (i.e., after childbirth), as well as the lengthy time
required for cell proliferation. Additionally, distinct
safety issues arise for both the mother and child for each
distinct harvesting method. Amniocentesis for harvest-
ing AFSCs may be associated with risks of harming the
mother and the child, while AMSCs can easily be
collected following childbirth without such risk of injury.
Alternatively, AFSCs can be collected following child-
birth, but this delayed harvest negates the aforemen-
tioned benefits of early harvesting. In addition, it is
easier to culture and amplify stem cells derived from the
amniotic membrane, because the amniotic membrane
contains more initial stem cells. However, despite the
initial low yield of stem cells derived from amniocen-
tesis, the time interval prior to childbirth allows more
time for cell amplification. Lastly, because AFSCs are
harvested from the fluid without specific landmark
features of the originating tissue source, phenotypically
defining these cells as a homogeneous cell population
may present as a technical challenge [5, 30–32]. Com-
pared with AMSCs, discrete regions of the amnion
membrane are largely well defined. For example, most
AMSCs are of epithelial and mesenchymal origins [33].
This understanding of the amnion membrane permits
for simpler methods to isolate and further differentiate
these cells into specific phenotypes. However, recent
studies have shown that secreted trophic factors, rather
than the differentiated stem cells themselves, mediate
most therapeutic effects [25, 34]. Thus, therapeutic
outcomes may be achieved regardless of generating a
homogenous stem cell population.
Tissue engineering & regenerative potential of amniotic
fluid stem cells
AFSCs and AFMSCs may be applied to tissue engineering
and regenerative medicine for stroke due to their
therapeutic properties. Both AFSCs/AFMSCs may act as
biobridges or subdural patch-like networks when treating
traumatic brain injury (TBI). AFMSCs may support
biobridge formation, which is demonstrated by the notch-
induced human bone marrow derived MSCs during
regeneration in rat brain following TBI incidence [35].
Biobridges allow both endogenous and exogenous stem
cells to transverse non-neurogenic tissue to the site of
injury, which can aid the suppression of damaging inflam-
mation. Additionally, no immune response is triggered
following the graft-host integration of the biobridge
formation, providing further evidence that amniotic fluid
subdural patches are a possible therapeutic option for
regenerative medicine. Such biobridge formation induced
by bone marrow MSCs in TBI may be extended to stroke
using AFSCs/AFMSCs.
Despite potential graft-versus-host disease issues aris-
ing from cell transplantation between species, xenografts
remain as a treatment option for a vast array of health
disorders, notably neurological diseases. Foreign cell and
tissue transplants are often rejected by the host’s
immune system. After transplantation of xenografts, the
graft is immediately rejected as xenoreactive antibodies
lead to complement activation and systemic inflamma-
tion [36, 37]. Many commonplace immune tolerance
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techniques, like neonatal desensitization, have failed to
increase the viability of the foreign transplant [38]. To
circumvent such poor xenograft survival, treatment with
circulating inflammatory alpha-1-antitrypsin (ATT) in
combination with anti-CD4/CD8 therapy may promote
graft acceptance [39]. In the same vein, AFMSCs’ anti-
inflammatory features may be honed to similarly suppress
xenograft rejection by co-transplantation of these
immunosuppressive amniotic fluid stem cells with xeno-
grafts. The ability of AFMSCs to abrogate the immune
and inflammatory reactions linked to xenografts may also
improve the therapeutic outcome of allograft transplant-
ation. The acceptance of an allograft is defined as a lack of
damaging reaction by the host’s immune system against
the foreign alloantigens of the graft. The immunomodula-
tory properties of AFMSCs may support allograft long-
term acceptance by hindering both the innate immune
response and the donor-specific adaptive immune
response, initiated by T-cell recognition of foreign alloan-
tigen [40]. Such blockade of deleterious effects of graft
rejection by AFMSCs may also circumvent the need for
chronic immunosuppression of the allograft [8, 41].
Conclusion
AFSCs have great clinical potential as graft source for
cell therapy in stroke. The simple isolation, amplifica-
tion, multiple opportunities to harvest, either through
amniocentesis or after birth, the increased amplification
time, the ability to differentiate into many distinct cell
lines, their immunomodulatory effects and lack of eth-
ical concerns associated with their therapeutic use make
AFSCs an effective source of stem cells. Transplantation
of AFSCs may be used in regenerative medicine, notably
in the therapeutic treatment of ischemic stroke due to
its neurogenesis, angiogenesis and immunomodulation
characteristics. However, further research must be
conducted to fully understand the vast therapeutic range
AFSCs may have in the clinical setting for stroke
patients. Investigating the potential of AFSCs could guide
further progress in the study of regenerative medicine,
eventually leading to their application in stroke.
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